Infed Related Published Studies
Well-designed clinical trials related to Infed (Iron Dextran)
A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. [2011.05]
Total infusion of low molecular weight iron-dextran for treating postpartum anemia. [2011]
Lipid peroxidation products formation with various intravenous iron preparations in chronic kidney disease. [2009]
Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease. [2007.09]
Iron therapy in the pediatric hemodialysis population. [2004.06]
Single-dose pharmacokinetics of sodium ferric gluconate complex in iron-deficient subjects. [2004.05]
Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. [2004.04.01]
A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. [2004.04]
A prospective, partially randomized study of pregnancy outcomes and hematologic responses to oral and intramuscular iron treatment in moderately anemic pregnant women. [2004.01]
Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. [2003.11]
A comparative study between intramuscular iron dextran and oral ferrous sulphate in the treatment of iron deficiency anaemia in pregnancy. [2003.11]
Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. [2003.01]
Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. [2002.05]
[Comparison of the efficacy of two different iron supplements for anemia prevention in piglets] [2002.02.15]
A randomized trial of iron deficiency testing strategies in hemodialysis patients. [2001.12]
Diagnostic value of iron indices in hemodialysis patients receiving epoetin. [2001.07]
Intravenous iron dextran treatment in predialysis patients with chronic renal failure. [2000.10]
Effects of iron dextran injections on the incidence of abomasal bloat, clinical pathology and growth rates in lambs. [2000.04.15]
Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. [2000.03]
Calcium does not inhibit iron absorption or alter iron status in infant piglets adapted to a high calcium diet. [1999.03]
Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial. [1998.03]
A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients. [1998.01]
Iron utilization after iron dextran administration for iron deficiency in patients with dialysis-associated anemia: a prospective analysis and comparison of two agents. [1996.12]
A randomized controlled study of iron supplementation in patients treated with erythropoietin. [1996.11]
Randomized cross-over study of adverse reactions and cost implications of intravenous push compared with infusion of iron dextran in hemodialysis patients. [1996.10]
Effect of iron-supplemented total parenteral nutrition in patients with iron deficiency anemia. [1996.06]
Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. [1995.07]
Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. [1995.03]
Intravenous iron administration to very-low-birth-weight newborns receiving total and partial parenteral nutrition. [1995.03]
New schedule of intramuscular iron administration for pregnant women. [1993.06]
Iron status with different infant feeding regimens: relevance to screening and prevention of iron deficiency. [1991.05]
Iron dextran in the treatment of iron-deficiency anaemia of pregnancy. Haematological response and incidence of side-effects. [1991.02.16]
Prevention of iron deficiency in preterm neonates during infancy. [1990.04.07]
Behavioral effects of iron supplementation in infants in Madang, Papua New Guinea. [1989.09]
Well-designed clinical trials possibly related to Infed (Iron Dextran)
The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. [1998.08.27]
The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less: a randomized, double-blind, placebo-controlled study. [1997.11]
Pharmacokinetics and effectiveness of recombinant erythropoietin administered to preterm infants by continuous infusion in total parenteral nutrition solution. [1996.04]
Effect of erythropoietin therapy and withdrawal on blood coagulation and fibrinolysis in hemodialysis patients. [1993.07]
Other research related to Infed (Iron Dextran)
Iron sucrose versus oral iron therapy in pregnancy anemia. [2012]
Effect of injected and dietary iron in young pigs on blood hematology and postnatal pig growth performance. [2011.12]
Safety profiles of total dose infusion of low-molecular-weight iron dextran and high-dose iron sucrose in renal patients. [2011.07]
Deferasirox protects against iron-induced hepatic injury in Mongolian gerbil. [2011.06]
Long-Term Efficacy of Deferasirox in Preventing Cardiovascular Complications in the Iron-Overloaded Gerbil. [2011.05.18]
Intravenous iron sucrose for children with iron deficiency failing to respond to oral iron therapy. [2011.04]
Accelerated total dose infusion of low molecular weight iron dextran is safe and efficacious in chronic kidney disease patients. [2011.03]
Comparison of oral versus parenteral iron supplementation on the health and productivity of piglets. [2011.02.19]
Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model. [2011]
Differences in spontaneously reported hypersensitivity and serious adverse events for intravenous iron preparations: comparison of Europe and North America. [2011]
Comparison of adverse-event profiles of intravenous low-molecular-weight iron dextran and iron sucrose in peritoneal dialysis patients. [2011]
Bone loss caused by iron overload in a murine model: importance of oxidative stress. [2010.10.07]
Use of parenteral iron products and serious anaphylactic-type reactions. [2010.09]
Safety and efficacy of total-dose infusion of low molecular weight iron dextran for iron deficiency anemia in patients with inflammatory bowel disease. [2010.08]
Iron-dextran injection into the substantia nigra in rats decreases striatal dopamine content ipsilateral to the injury site and impairs motor function. [2010.06]
Intravenous iron dextran for severe refractory restless legs syndrome. [2010.05]
Comparison of the prophylactic effect of silymarin and deferoxamine on iron overload-induced hepatotoxicity in rat. [2010.03]
Iron replacement therapy: assessing today's options to prepare for bundling. [2010.02]
Neuroprotective effects of tempol on retinal ganglion cells in a partial optic nerve crush rat model with and without iron load. [2010.02]
Low-molecular-weight iron dextran in the management of renal anaemia in patients on haemodialysis--the IDIRA Study. [2010]
Clinical use of intravenous iron: administration, efficacy, and safety. [2010]
Physical and chemical stability of iron sucrose in parenteral nutrition. [2009.12]
Evolution of iv iron compounds over the last century. [2009.12]
Nephrogenic systemic fibrosis in rats treated with erythropoietin and intravenous iron. [2009.11]
Intravenous iron in inflammatory bowel disease. [2009.10.07]
A novel short-course regimen of intramuscular iron therapy for anaemic pregnant women. [2009.10]
Effects of Parenteral Supply of Iron on RBC Parameters, Performance, and Health in Neonatal Dairy Calves. [2009.09.15]
Deferasirox removes cardiac iron and attenuates oxidative stress in the iron-overloaded gerbil. [2009.09]
Iron supplementation by intraperitoneal injection eliminates the accumulation of hepatic copper induced by excess calcium in rats. [2009.07]
Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease. [2009.06]
Novel iron-polysaccharide multilayered microcapsules for controlled insulin release. [2009.06]
Physicochemical properties of ferumoxytol, a new intravenous iron preparation. [2009.06]
Use of iron sucrose in dialysis patients sensitive to iron dextran. [2009.03]
Parenteral iron use: possible contribution to exceeding target hemoglobin in hemodialysis patients. [2009.03]
The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data. [2009.02.26]
Regulation of iron metabolism-related genes in diethylnitrosamine-induced mouse liver tumors. [2009.02.10]
Effects of intracerebroventricular injection of iron dextran on the iron concentration and divalent metal transporter 1 expression in the caudate putamen and substantia nigra of rats. [2009.02]
Biofortified black beans in a maize and bean diet provide more bioavailable iron to piglets than standard black beans. [2009.02]
The role of iron supplementation during epoietin treatment for cancer-related anemia. [2009]
Iron overload detection in rats by means of a susceptometer operating at room temperature. [2008.12.07]
Safety issues with intravenous iron products in the management of anemia in chronic kidney disease. [2008.12]
Improving efficiency and value in health care. Intravenous iron management for anaemia associated with chronic kidney disease: linking treatment to an outpatient clinic, optimizing service provision and patient choice. [2008.12]
Effects of parenteral supply of iron and copper on hematology, weight gain, and health in neonatal dairy calves. [2008.10]
Iron injection restores brain iron and hemoglobin deficits in perinatal copper-deficient rats. [2008.10]
Effects of neonatal iron status, iron injections at birth, and weaning in young pigs from sows fed either organic or inorganic trace minerals. [2008.09]
Intravenous iron administration in a short-stay hospital setting. [2008.08.06]
Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy. [2008.07]
Intravenous iron in oncology. [2008.07]
Effects of parenteral supply of iron and copper on hematology, weight gain, and health in neonatal dairy calves. [2008.05.14]
Dysregulation of hepatic iron with aging: implications for heat stress-induced oxidative liver injury. [2008.04]
Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease. [2008.03]
Safety and efficacy of total dose infusion of iron dextran in iron deficiency anaemia. [2008.03]
[Effect of chronic iron overload on atherosclerosis lesion in apolipoprotein E knockout mice.] [2008.02]
[Effect of chronic iron overload on atherosclerosis lesion in apolipoprotein E knockout mice] [2008.01]
The comparative safety of various intravenous iron preparations in chronic kidney disease patients. [2008]
Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload. [2008]
Iron preloading aggravates nutritional steatohepatitis in rats by increasing apoptotic cell death. [2007.12]
Effect of an oral iron chelator or iron-deficient diets on uroporphyria in a murine model of porphyria cutanea tarda. [2007.12]
Differential expression of stress-inducible proteins in chronic hepatic iron overload. [2007.09.01]
Risk of infection with intravenous iron therapy. [2007.09]
Iron does not cause arrhythmias in the guinea pig model of transfusional iron overload. [2007.08]
Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy. [2007.07]
The dose-dependent effects of chronic iron overload on the production of oxygen free radicals and vitamin E concentrations in the liver of a murine model. [2007.04]
|
